Fallopian Tube Carcinoma

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Celldex Therapeutics
1 program
1
DEC-205/NY-ESO-1 Fusion Protein CDX-1401Phase 1/21 trial
Active Trials
NCT02166905Completed40Est. Aug 2020
E
EisaiChina - Liaoning
1 program
1
Lenvatinib MesylatePhase 11 trial
Active Trials
NCT02788708Completed26Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Celldex TherapeuticsDEC-205/NY-ESO-1 Fusion Protein CDX-1401
EisaiLenvatinib Mesylate

Clinical Trials (2)

Total enrollment: 66 patients across 2 trials

NCT02166905Celldex TherapeuticsDEC-205/NY-ESO-1 Fusion Protein CDX-1401

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Start: Oct 2014Est. completion: Aug 202040 patients
Phase 1/2Completed
NCT02788708EisaiLenvatinib Mesylate

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Start: May 2016Est. completion: Mar 202226 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space